Redeye provides its first take on Oncopeptides’ Q3 report 2026. Sales fell 8.5% Q/Q to SEK28.5m, from SEK31.1m in Q2, but grew 41% Y/Y from SEK20.2m in Q3 2025. The topline was 17% below our estimate of SEK34.2m.
ANNONS
Redeye provides its first take on Oncopeptides’ Q3 report 2026. Sales fell 8.5% Q/Q to SEK28.5m, from SEK31.1m in Q2, but grew 41% Y/Y from SEK20.2m in Q3 2025. The topline was 17% below our estimate of SEK34.2m.
